Document text
Principal Investigator: Juhun Lee
Organization: UNIVERSITY OF PITTSBURGH AT PITTSBURGH
Fiscal Year: 2024
Award: $330,868
Funding agency: National Cancer Institute
Most women in the USA who have dense breasts at screening mammography receive a letter notifying them
that mammography is less effective for them and having dense breasts increases the risk of breast cancer.
The letter advises women to talk with their physician whether they should have additional screening with
ultrasound or magnetic resonance imaging (MRI). The possible benefit of additional screening is detecting a
mammographically occult (MO) cancer. However, the likelihood that a woman has a missed cancer is not
known. Thus, women are left with a difficult decision, balancing the uncertain potential benefit of additional
screening against the known costs. These known costs are financial (as some states do not cover the
supplemental screen) and the risk of an unnecessary biopsy, as the specificity of ultrasound and MRI are lower
than mammography. We have developed a novel technique using a Radon Cumulative Distribution Transform
(RCDT) to detect MO cancers. The RCDT can highlight subtle suspicious signals by detecting asymmetries
between the left and right mammograms. Our technique achieved an area under the ROC curve of 0.81 using
screening mammograms. Digital breast tomosynthesis (DBT), a pseudo-3D imaging technique, is replacing
mammography in the USA, because of its higher sensitivity and specificity. However, MO cancers still exist in
DBT. The goal of our research is to develop imaging biomarkers for MO cancers on screening DBT of women
with dense breasts. This would allow women to know the likelihood that they have an MO cancer and, thereby,
allow them to make a more informed choice regarding supplemental screening. The key difference between
DBT and standard 2D mammography is the available information in the z-direction. Such additional information
provides advantages for cancer detection, but it also adds technical complexity when applying RCDT on DBT
images. There are three ways to process DBT exams for RCDT: 1) applying RCDT on 2D DBT slices, 2)
applying RCDT on synthetic mammograms from DBT, and 3) applying the 3D RCDT on DBT volumes. To
develop imaging biomarkers for MO cancer in screening DBT, we need to investigate the optimal method to
process DBT for RCDT. We will develop imaging biomarkers for the three methods using a developmental
dataset of 900 MO cancer cases (clinical cases read as normal, but the woman has breast cancer detected on
her next screening DBT) and 1800 cases (clinical cases read as normal and the woman does not have breast
cancer detected on her next two screening DBTs). We will utilize a 2D convolutional neural network (CNN) and
a 3D CNN as robust classifiers to analyze the RCDT processed DBT for MO cancer detection. Using a 5-fold
cross-validation, we will train CNNs for each method and find the optimal method to process DBT for MO
cancer detection. Finally, we will use an independent dataset of 100 cases to validate the classifier. If we are
successful, then up to 15 million women each year who have dense breasts will have needed information upon
which to base their decision for getting supplemental screening.
Terms: <3-D><3-D Imaging><3-Dimensional><3D><3D imaging><AI based method><Area><Biopsy><Body Tissues><Breast><Breast Cancer><Breast Cancer Detection><Breast Cancer Risk Factor><Breast MRI><Breast Magnetic Resonance Imaging><Breast Tissue><Breast cancer screening><Breast screening><Cancer Detection><Cancers><Cell Communication and Signaling><Cell Signaling><Clinical><Consult><ConvNet><Data Set><Development><Digital Breast Tomosynthesis><Digital Mammography><Financial cost><Future><Goals><Image><Imaging Procedures><Imaging Technics><Imaging Techniques><Individual><Intracellular Communication and Signaling><Investigators><Lateral><Laws><Lead><Left><Letters><MR Imaging><MR Tomography><MRI><MRIs><Magnetic Resonance Imaging><Malignant Breast Neoplasm><Malignant Neoplasms><Malignant Tumor><Mammary Gland Parenchyma><Mammary Gland Tissue><Mammogram><Mammographic screening><Mammography><Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance><Methods><Modality><Modeling><NMR Imaging><NMR Tomography><Notification><Nuclear Magnetic Resonance Imaging><Pb element><Physicians><Process><ROC Analyses><ROC Curve><Radon><Recommendation><Research><Research Personnel><Researchers><Risk><Rn element><Scanning><Sensitivity and Specificity><Signal Transduction><Signal Transduction Systems><Signaling><Slice><Specificity><Target Populations><Techniques><Testing><Thick><Thickness><Three-Dimensional Imaging><Tissues><Training><Translating><Validation><Woman><Zeugmatography><artificial intelligence method><base><bases><biological signal transduction><biomarker validation><breast cancer risk><breast density><breast imaging><consults><convolutional network><convolutional neural nets><convolutional neural network><cost><developmental><digital><facilities for imaging><heavy metal Pb><heavy metal lead><high risk><imaging><imaging biomarker><imaging center><imaging facilities><imaging marker><imaging-based biological marker><imaging-based biomarker><imaging-based marker><imaging-related facilities><malignancy><malignant breast tumor><mammary cancer detection><mammary imaging><mammary screening><mammographic Imaging><mammographic examinations><mammographic exams><mammography screening><marker validation><monetary cost><neoplasm/cancer><novel><receiver operating characteristic analyses><receiver operating characteristic curve><screening><screenings><supplemental screening><three dimensional><tomosynthesis><ultrasound><validations>